MEDEXUS PHARMACEUTICALS INC (MDP.CA) Stock Fundamental Analysis
Canada - TSX:MDP - CA58410Q2036 - Common Stock
2.94 CAD
-0.05 (-1.67%)
Taking everything into account, MDP scores 5 out of 10 in our fundamental rating. MDP was compared to 34 industry peers in the Pharmaceuticals industry. MDP has only an average score on both its financial health and profitability. MDP is valued quite cheap, while showing a decent growth score. This is a good combination!
1. Profitability
1.1 Basic Checks
MDP had positive earnings in the past year.
In the past year MDP had a positive cash flow from operations.
In multiple years MDP reported negative net income over the last 5 years.
The reported operating cash flow has been mixed in the past 5 years: MDP reported negative operating cash flow in multiple years.
1.2 Ratios
MDP has a Return On Assets of 0.52%. This is in the better half of the industry: MDP outperforms 79.41% of its industry peers.
MDP has a Return On Equity of 1.52%. This is in the better half of the industry: MDP outperforms 79.41% of its industry peers.
MDP's Return On Invested Capital of 8.11% is amongst the best of the industry. MDP outperforms 91.18% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for MDP is above the industry average of 7.74%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.52% | ||
| ROE | 1.52% | ||
| ROIC | 8.11% |
ROA(3y)0.64%
ROA(5y)-3.83%
ROE(3y)3.01%
ROE(5y)-32.83%
ROIC(3y)9.89%
ROIC(5y)N/A
1.3 Margins
With a decent Profit Margin value of 0.76%, MDP is doing good in the industry, outperforming 70.59% of the companies in the same industry.
MDP has a Operating Margin of 7.99%. This is in the better half of the industry: MDP outperforms 79.41% of its industry peers.
The Gross Margin of MDP (52.55%) is better than 82.35% of its industry peers.
MDP's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 7.99% | ||
| PM (TTM) | 0.76% | ||
| GM | 52.55% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.84%
GM growth 5Y-1.43%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so MDP is still creating some value.
MDP has more shares outstanding than it did 1 year ago.
MDP has more shares outstanding than it did 5 years ago.
The debt/assets ratio for MDP has been reduced compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of 0.60, we must say that MDP is in the distress zone and has some risk of bankruptcy.
MDP has a Altman-Z score of 0.60. This is in the better half of the industry: MDP outperforms 67.65% of its industry peers.
The Debt to FCF ratio of MDP is 1.29, which is an excellent value as it means it would take MDP, only 1.29 years of fcf income to pay off all of its debts.
With an excellent Debt to FCF ratio value of 1.29, MDP belongs to the best of the industry, outperforming 94.12% of the companies in the same industry.
MDP has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
With an excellent Debt to Equity ratio value of 0.00, MDP belongs to the best of the industry, outperforming 88.24% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 1.29 | ||
| Altman-Z | 0.6 |
ROIC/WACC0.83
WACC9.74%
2.3 Liquidity
MDP has a Current Ratio of 0.81. This is a bad value and indicates that MDP is not financially healthy enough and could expect problems in meeting its short term obligations.
MDP has a Current ratio of 0.81. This is amonst the worse of the industry: MDP underperforms 88.24% of its industry peers.
A Quick Ratio of 0.37 indicates that MDP may have some problems paying its short term obligations.
With a Quick ratio value of 0.37, MDP is not doing good in the industry: 85.29% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.81 | ||
| Quick Ratio | 0.37 |
3. Growth
3.1 Past
MDP shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -50.00%.
Looking at the last year, MDP shows a decrease in Revenue. The Revenue has decreased by -2.87% in the last year.
The Revenue has been growing slightly by 7.82% on average over the past years.
EPS 1Y (TTM)-50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-75%
Revenue 1Y (TTM)-2.87%
Revenue growth 3Y12.2%
Revenue growth 5Y7.82%
Sales Q2Q%-9.78%
3.2 Future
MDP is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 53.29% yearly.
Based on estimates for the next years, MDP will show a quite strong growth in Revenue. The Revenue will grow by 10.19% on average per year.
EPS Next Y-175.75%
EPS Next 2Y90.52%
EPS Next 3Y104.09%
EPS Next 5Y53.29%
Revenue Next Year-5.78%
Revenue Next 2Y4.88%
Revenue Next 3Y8.74%
Revenue Next 5Y10.19%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 98.00, which means the current valuation is very expensive for MDP.
Compared to the rest of the industry, the Price/Earnings ratio of MDP indicates a somewhat cheap valuation: MDP is cheaper than 76.47% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.41, MDP is valued quite expensively.
A Price/Forward Earnings ratio of 7.32 indicates a rather cheap valuation of MDP.
88.24% of the companies in the same industry are more expensive than MDP, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 22.87. MDP is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 98 | ||
| Fwd PE | 7.32 |
4.2 Price Multiples
97.06% of the companies in the same industry are more expensive than MDP, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, MDP is valued cheaper than 91.18% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 4.05 | ||
| EV/EBITDA | 4.88 |
4.3 Compensation for Growth
The decent profitability rating of MDP may justify a higher PE ratio.
MDP's earnings are expected to grow with 104.09% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y90.52%
EPS Next 3Y104.09%
5. Dividend
5.1 Amount
No dividends for MDP!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX:MDP (9/23/2025, 7:00:00 PM)
2.94
-0.05 (-1.67%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners2.98%
Inst Owner ChangeN/A
Ins Owners7.25%
Ins Owner ChangeN/A
Market Cap94.84M
Analysts80
Price Target6.3 (114.29%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)101.23%
Min EPS beat(2)58.46%
Max EPS beat(2)144%
EPS beat(4)3
Avg EPS beat(4)43.05%
Min EPS beat(4)-100%
Max EPS beat(4)144%
EPS beat(8)5
Avg EPS beat(8)4.43%
EPS beat(12)9
Avg EPS beat(12)92.45%
EPS beat(16)10
Avg EPS beat(16)67.52%
Revenue beat(2)0
Avg Revenue beat(2)-0.53%
Min Revenue beat(2)-0.63%
Max Revenue beat(2)-0.44%
Revenue beat(4)1
Avg Revenue beat(4)1.34%
Min Revenue beat(4)-0.63%
Max Revenue beat(4)6.82%
Revenue beat(8)2
Avg Revenue beat(8)-2.13%
Revenue beat(12)5
Avg Revenue beat(12)0.19%
Revenue beat(16)8
Avg Revenue beat(16)1.71%
PT rev (1m)-4.42%
PT rev (3m)0.93%
EPS NQ rev (1m)71.43%
EPS NQ rev (3m)-127.27%
EPS NY rev (1m)0%
EPS NY rev (3m)37.5%
Revenue NQ rev (1m)-0.39%
Revenue NQ rev (3m)5.62%
Revenue NY rev (1m)-0.4%
Revenue NY rev (3m)0.84%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 98 | ||
| Fwd PE | 7.32 | ||
| P/S | 0.65 | ||
| P/FCF | 4.05 | ||
| P/OCF | 3.47 | ||
| P/B | 1.3 | ||
| P/tB | N/A | ||
| EV/EBITDA | 4.88 |
EPS(TTM)0.03
EY1.02%
EPS(NY)0.4
Fwd EY13.66%
FCF(TTM)0.73
FCFY24.7%
OCF(TTM)0.85
OCFY28.81%
SpS4.53
BVpS2.27
TBVpS-1.15
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.52% | ||
| ROE | 1.52% | ||
| ROCE | 11.27% | ||
| ROIC | 8.11% | ||
| ROICexc | 9.27% | ||
| ROICexgc | N/A | ||
| OM | 7.99% | ||
| PM (TTM) | 0.76% | ||
| GM | 52.55% | ||
| FCFM | 16.03% |
ROA(3y)0.64%
ROA(5y)-3.83%
ROE(3y)3.01%
ROE(5y)-32.83%
ROIC(3y)9.89%
ROIC(5y)N/A
ROICexc(3y)12.45%
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)13.73%
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.84%
GM growth 5Y-1.43%
F-Score5
Asset Turnover0.69
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 1.29 | ||
| Debt/EBITDA | 0.01 | ||
| Cap/Depr | 34.4% | ||
| Cap/Sales | 2.67% | ||
| Interest Coverage | 2.18 | ||
| Cash Conversion | 118.79% | ||
| Profit Quality | 2101.86% | ||
| Current Ratio | 0.81 | ||
| Quick Ratio | 0.37 | ||
| Altman-Z | 0.6 |
F-Score5
WACC9.74%
ROIC/WACC0.83
Cap/Depr(3y)16.17%
Cap/Depr(5y)70.8%
Cap/Sales(3y)1.03%
Cap/Sales(5y)5.33%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-75%
EPS Next Y-175.75%
EPS Next 2Y90.52%
EPS Next 3Y104.09%
EPS Next 5Y53.29%
Revenue 1Y (TTM)-2.87%
Revenue growth 3Y12.2%
Revenue growth 5Y7.82%
Sales Q2Q%-9.78%
Revenue Next Year-5.78%
Revenue Next 2Y4.88%
Revenue Next 3Y8.74%
Revenue Next 5Y10.19%
EBIT growth 1Y-31.25%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year45.11%
EBIT Next 3Y60.67%
EBIT Next 5Y50.41%
FCF growth 1Y164.21%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y191.19%
OCF growth 3YN/A
OCF growth 5YN/A